歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01672 歌礼制药-B

休市中 07-24 16:08:05

9.020

+0.180

+2.04%

最高9.060	最低8.470	成交量242.00万
今开8.480	昨收8.840	日振幅6.67%
总市值94.89亿	流通市值94.89亿	总股本10.52亿
成交额2,137万	换手率0.23%	流通股本10.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":9.02,"timestamp":1784880485003,"preClose":8.84,"halted":0,"volume":2420000,"delay":0,"changeRate":0.020361990950226214,"floatShares":1052000000,"shares":1052000000,"eps":-0.3701,"marketStatus":"休市中","change":0.18,"latestTime":"07-24 16:08:05","open":8.48,"high":9.06,"low":8.47,"amount":21366526,"amplitude":0.066742,"askPrice":9.05,"askSize":9000,"bidPrice":9,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-0.379,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":7,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":8.84,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.6201424523589656,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"1184171845","title":"歌礼制药-B7月24日回购200,000股股份，总额约178.36万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184171845","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184171845?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:21","pubTimestamp":1784888493,"startTime":"0","endTime":"0","summary":"歌礼制药-B于2026年7月24日在香港联交所场内回购200,000股普通股，约占公司当日已发行股本的0.019%。回购价格介乎每股8.74港元至9.03港元，总耗资约178.36万港元。回购后，公司已发行股本仍为1,051,984,845股，库藏股数量为5,784,210股，合计股份总数1,057,769,055股。公告显示，此次回购基于2026年6月29日通过的购回授权进行，授权剩余可回购股份总数为106,137,084股。公司确认本次回购已遵守香港联交所证券上市规则及相关法律法规。公告由公司秘书钟明辉签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B7月24日回购200,000股股份，总额约178.36万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653085682","title":"歌礼制药-B(01672.HK)7月24日斥资178.36万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653085682","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653085682?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:08","pubTimestamp":1784887730,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","01672","BK1161","BK1515","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653928557","title":"歌礼制药：将在第62届EASD年会上汇报用于治疗肥胖症的ASC36_35 FDC临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2653928557","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653928557?lang=zh_cn&edition=full","pubTime":"2026-07-23 08:26","pubTimestamp":1784766364,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1515","BK1574","BK1161","BK1191","01477","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114222229","title":"歌礼制药将在欧洲糖尿病研究协会年会口头报告ASC36_35 FDC临床前数据，显示其减重效果优于艾拉兰肽/替尔泊肽复方制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1114222229","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114222229?lang=zh_cn&edition=full","pubTime":"2026-07-23 08:13","pubTimestamp":1784765600,"startTime":"0","endTime":"0","summary":"歌礼制药-B宣布，其口服小分子药物ASC36_35固定剂量复方的临床前研究数据，将在第62届欧洲糖尿病研究协会年会上进行口头讨论。数据显示，该药物在减重方面表现出优于艾拉兰肽与替尔泊肽联合疗法的潜力。这项研究结果的展示，标志着歌礼制药在代谢疾病治疗领域，特别是针对肥胖症的新型口服疗法开发上，取得了重要进展。ASC36_35 FDC作为一种口服制剂，若其疗效在后续临床试验中得到证实，将为患者提供比现有注射疗法更为便捷的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","MHIP","IE0009355771.USD","LU0097036916.USD","SGXZ99366536.SGD","BK4007","LU0345770993.USD","PJP","LU0174119429.USD","LU0823434583.USD","LU2087625088.SGD","SG9999001176.SGD","LU0006306889.USD","IE00B2B36J28.USD","LU0964807845.USD","LU0058720904.USD","LU2237443895.HKD","LU0158827948.USD","IE00BN29S564.USD","IE00B4R5TH58.HKD","IE0002141913.USD","IE0004445239.USD","IXJ","LU1064131342.USD","LU1868836914.USD","LU2471134523.USD","LU0683600562.USD","LU1623119135.USD","LU2491050154.USD","SG9999015986.USD","LU0456855351.SGD","LU2462157665.USD","SGXZ31699556.SGD","SGXZ51526630.SGD","LU2552382058.USD","LU0320765992.SGD","LU2023251221.USD","LU2456880835.USD","IE00BK4W5L77.USD","LU1868837136.USD","LU0256863811.USD","LU1983299246.USD","IE00BKPKM429.USD","LU0354030438.USD","LU0889565916.HKD","LU1023059063.AUD","IE00BJT1NW94.SGD","LU1127390331.HKD","LU2361044949.HKD","TRUH","IE00BFSS7M15.SGD","LU2756315318.SGD","LU0256863902.USD","LU0122379950.USD","IE00BK4W5M84.HKD","IE00B4JS1V06.HKD","LU0158827781.USD","LU2237443465.HKD","LU2237443549.SGD","SG9999013999.USD","XLV","01672","LU2112291526.USD","IE0005OL40V9.USD","ILDR","BK4533","LU0316494557.USD","IHE","LU1291159041.SGD","LU2213496289.HKD","LU2089284900.SGD","WDNA","CANC","LU0345770308.USD","GB00BDT5M118.USD","LU0823434740.USD","LU2491049909.HKD","LU2602419157.SGD","LU0323591593.USD","LU0672654240.SGD","LU2168564495.EUR","LU0203202063.USD","IE00BJJMRX11.SGD","LU1868836757.USD","IYH","LU0823416689.USD","MEDI","LU2462591350.SGD","LU0708995401.HKD","LU1057294990.SGD","LU2106854487.HKD","LU0385154629.USD","LU1093756168.USD","LU0133085943.USD","LU0882574139.USD","LU2108987350.USD","LU2461242641.AUD","IE00BWXC8680.SGD","LLYZ","LU2089283258.USD","LU2324357040.USD","MEDX","LU0114720955.EUR","IE00BJJMRZ35.SGD","LU2023250504.SGD","LU2746668974.SGD","IE00B1BXHZ80.USD","LU1280957306.USD","LU1551013425.SGD","LU2491050071.SGD","FHLC","BK1574","BK4588","LU0266013472.USD","LU0061475181.USD","LU0210536198.USD","IE00B775H168.HKD","LU1061106388.HKD","LU2552382215.SGD","SG9999015945.SGD","SG9999015952.SGD","LU1868836591.USD","LU1720051108.HKD","LU2552382132.HKD","LU2265009873.SGD","LU2168563687.JPY","LU2028103732.USD","BK4516","LU2360106947.USD","LU1988902786.USD","LU1629891620.HKD","LU2750360997.AUD","LU0466842654.USD","THNR","LU2264538146.SGD","RXL","LU2168564222.USD","LU1974910355.USD","LU1548497426.USD","LU1551013342.USD","BK1515","LU0353189680.USD","LU0432979614.USD","LLII","LU0234572021.USD","IE00BFSS8Q28.SGD","LU0106261372.USD","LU0820562030.AUD","LU1323610961.USD","LU2361045086.USD","ELIL","LU1989771016.USD","SG9999014880.SGD","LU1069344957.HKD","LU2211815571.USD","LU0820561818.USD","LU2750360641.GBP","LLY","LU0198837287.USD","BK4599","LU0943347566.SGD","GDOC","LU2023250330.USD","LU2471134952.CNY","IE00BJLML261.HKD","IE00BKDWB100.SGD","LU1093756325.SGD","AGNG","LLYX","LU2237438978.USD","LU2746668461.USD","LU0471298777.SGD","BK4534","LU0417517546.SGD","SG9999017495.SGD","LU2237443978.SGD","LU0109391861.USD","LU1232071149.USD","PPH","LU0471298694.HKD","LU2063271972.USD","SG9999018865.SGD","LU0786609619.USD","LU0787776722.HKD","LU0225283273.USD","TMED","LU0640476718.USD","LU1917777945.USD","LU0820561909.HKD","LU2357305700.SGD","LU1712237335.SGD","IE00B7KXQ091.USD","LU2471134796.USD","LU1804176565.USD","FTXH","SG9999001176.USD","LU2468319806.SGD","LU1868837300.USD","LU0353189763.USD","SGXZ57979304.SGD","ELIS","LU0203201768.USD","LU2361044865.SGD","LU2089984988.USD","LU1035775433.USD","LU2236285917.USD","LU1366192091.USD","SG9999014898.SGD","IE0004445015.USD","LU2896262040.SGD","BK1161","BK4581","LU2471134879.HKD","LU0238689110.USD","OZEM","LU0882574055.USD","LU2111349929.HKD","LU1145028129.USD","LU2756315664.SGD","BK4585","LU2417539215.USD","CURE","LU0354030511.USD","LU0079474960.USD","LU2237443382.USD","LU0094547139.USD","LU1267930730.SGD","VHT","LU0289739699.SGD","JDOC","LU1814569148.SGD","SG9999014906.USD","LU1720051017.SGD","LU0109394709.USD","LU0689472784.USD","LU2168564149.EUR","IE00B1XK9C88.USD","LU0320765059.SGD","SG9999014914.USD","LU2168564065.EUR","IE0001KFT4U8.USD","LU2237443622.USD","LU2271345857.HKD","HRTS","SG9999018857.SGD","SGXZ81514606.USD","IE00BJJMRY28.SGD","SG9999015978.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158288652","title":"歌礼制药-B：ASC36_35 FDC减重前临床数据入选EASD 2026年会口头讨论","url":"https://stock-news.laohu8.com/highlight/detail?id=1158288652","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158288652?lang=zh_cn&edition=full","pubTime":"2026-07-23 08:05","pubTimestamp":1784765128,"startTime":"0","endTime":"0","summary":"2026年7月23日，歌礼制药-B发布自愿性公告称，其用于治疗肥胖症的每月一次注射复方制剂ASC36_35 FDC将在第62届欧洲糖尿病研究协会年会上以简短口头讨论形式报告临床前研究成果。根据公告，ASC36_35 FDC由多肽胰淀素受体激动剂ASC36与多肽GLP-1R/GIPR激动剂ASC35按一定比例共混而成，采用自组装脂质储库型制剂形式，每月皮下注射一次。EASD年会将于2026年9月28日至10月2日在意大利米兰举行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653794165","title":"歌礼制药-B(01672.HK)将在第62届欧洲糖尿病研究协会(EASD)年会上以口头讨论形式汇报ASC36_35 FDC减重效果优于 eloralintide联合tirzepatide的临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2653794165","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653794165?lang=zh_cn&edition=full","pubTime":"2026-07-23 08:03","pubTimestamp":1784765010,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1191","BK1574","01672","01477","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653737554","title":"港股异动 | 歌礼制药-B(01672.HK)涨超4% 公司口服双靶点复方再落子 有望进一步拓展ASC30平台价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2653737554","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653737554?lang=zh_cn&edition=full","pubTime":"2026-07-22 15:17","pubTimestamp":1784704624,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01672","BK1515","BK1161","BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152350979","title":"歌礼制药-B：7月21日回购20万股股份，耗资约169.02万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1152350979","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152350979?lang=zh_cn&edition=full","pubTime":"2026-07-21 18:16","pubTimestamp":1784629016,"startTime":"0","endTime":"0","summary":"2026年7月21日，歌礼制药有限公司公布翌日披露报表，披露在香港联交所场内回购200,000股普通股股份，最高回购价为每股8.65港元，最低回购价为每股8.01港元，合计支付约169.02万港元，占本次事件前已发行股本的0.0188%。公司此前于2026年6月29日通过股份购回授权，可回购股份总数为106,137,084股，截至公告日已于香港联交所或其他证券交易所累积回购1,345,000股，约占授权通过当日已发行股本的0.1267%。公司声明所有回购及注销程序均符合香港联交所证券上市规则及相关法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：7月21日回购20万股股份，耗资约169.02万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176484384","title":"歌礼制药-B：7月20日回购10万股股份，总额约88.13万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176484384","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176484384?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:21","pubTimestamp":1784542893,"startTime":"0","endTime":"0","summary":"2026年7月20日，歌礼制药-B发布翌日披露报表。公告显示，公司于当日于香港联交所场内回购普通股10.00万股，约占已发行股本的0.0094%。每股回购价格介乎8.61港元至9.02港元，合计耗资约88.13万港元。公司获股东大会于2026年6月29日通过的回购授权，可回购股份总数为10.61亿股，至今已累计在交易所以及其他证券交易所回购114.50万股，占授权通过时已发行股本的约0.1079%。公告同时显示，公司确认已遵守香港联交所证券上市规则及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：7月20日回购10万股股份，总额约88.13万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652292587","title":"歌礼制药-B(01672.HK)7月20日斥资88.13万港元回购10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652292587","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652292587?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:15","pubTimestamp":1784542504,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1515","01672","BK1161","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652269822","title":"创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652269822","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652269822?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:26","pubTimestamp":1784514372,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块活跃，荣昌生物 涨7.28%，歌礼制药-B涨6.81%，科伦博泰生物涨6.70%，康诺亚-B涨6.25%，康方生物涨5.83%，药明合联涨5.53%，石药集团涨4.94%，三生制药涨5.02%，信达生物涨4.55%，药明生物涨4.60%，恒瑞医药涨4.00%，百济神州涨3.88%。头部机构密集触及举牌线，凸显对创新药板块的看好。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986240","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","01672","LU0348735423.USD","01276","BK1588","LU1242518931.SGD","01093","02162","LU0043850808.USD","LU0348827113.USD","LU0708995583.HKD","02269","LU0417516738.SGD","LU2399975544.HKD","01801","02268","LU0052750758.USD","LU0196878994.USD","LU1064130708.USD","BK1576","SG9999002463.SGD","LU1242518857.USD","09995","LU1226288170.HKD","688331","KURE","LU1720050803.USD","LU1951186391.HKD","BK1593","159992","LU0516422440.USD","LU2097828474.EUR","06978","MEDX","LU0359201612.USD","BK0239","VXUS","KCAI","09926","LU0516423174.USD","01530","IBBQ","BK4585","HK0000165453.HKD","LU0516422366.SGD","LU0979878070.USD","LU0327786744.USD","LU2328871848.SGD","IE00BZ08YT58.USD","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133086822","title":"歌礼制药-B7月17日回购30万股，涉资约258.03万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133086822","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133086822?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:56","pubTimestamp":1784282196,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年7月17日公告，该公司在香港联交所场内回购30万股普通股，占公司已发行股本约0.0283%。每股回购价格介乎每股8.19港元至9.63港元之间，合计耗资约258.03万港元。公告显示，回购完成后，公司已发行普通股数量维持在1,061,370,845股，另有7,084,210股为库藏股，总股本为1,068,455,055股。截至公告日，公司已累计在交易所和其他证券交易所回购1,045,000股，占购回授权获批时已发行股本的约0.0985%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B7月17日回购30万股，涉资约258.03万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652401449","title":"歌礼制药-B(01672)7月17日斥资258.03万港元回购30万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652401449","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652401449?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:44","pubTimestamp":1784281460,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年7月17日斥资258.03万港元回购30万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","01672","01477","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651341039","title":"创新药连续大涨，这次真的不一样了吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2651341039","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651341039?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:05","pubTimestamp":1784192720,"startTime":"0","endTime":"0","summary":"政策上，医保初审通过率创新高，定价机制优化，并建立“医保+商保”双层支付体系；产业上，上半年BD交易总额达1100亿美元，国际竞争力显著提升；资金面上，内外资持续回流。行业正从“讲故事”转向盈利兑现，国金证券认为，2027年有望成为中国创新药海外商业化集中兑现的重要节点。","market":"hk","thumbnail":"https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3777107","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","06978","02268","06622","06606","03759","IBBQ","01801","BK1574","BK1161","02269","02137","09688","00241","09995","06996","03347","06618","01672","09606","02359","09966","MEDX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1165734166","title":"歌礼制药-B：ASC30_48复方制剂在非人灵长类研究中显示体重降幅较ASC30单药疗法提升52%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165734166","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165734166?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:02","pubTimestamp":1784109743,"startTime":"0","endTime":"0","summary":"歌礼制药-B宣布，其ASC30_48固定剂量复方制剂在非人灵长类动物研究中取得积极结果。数据显示，与ASC30单药疗法相比，该复方制剂在降低体重方面展现出显著优势，体重降幅提升了52%。这一发现为后续的临床开发提供了有力的非临床数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01672","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651451892","title":"歌礼制药-B(01672)选定同类首创口服小分子GIPR激动剂ASC48和口服小分子 GLP-1R激动剂ASC30的固定剂量复方制剂进行临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2651451892","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651451892?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:52","pubTimestamp":1784109149,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，已选定有望成为同类首创 口服小分子的GIPR激动剂ASC48，和口服小分子GLP-1R激动剂ASC30的固定剂量复方制剂进行临床开发。连续八天每日一次口服ASC30_48 FDC，其减重效果较ASC30及ASC48单药分别相对提升52%和518%。预计将于2026年第四季度向美国食品药品监督管理局递交ASC30_48 FDC 口服片的新药临床试验申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1574","BK4590","BK1515","BK1161","BK4160","GIPR","GLP","JDOC","01477","BK1191","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651451818","title":"歌礼制药-B(01672.HK)选定同类首创口服小分子GIPR激动剂ASC48和口服小分子 GLP-1R激动剂ASC30的固定剂量复方制剂进行临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2651451818","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651451818?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:52","pubTimestamp":1784109149,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01477","BK1515","BK1574","BK1161","01672","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135602038","title":"歌礼制药-B：7月15日回购20万股，耗资约210.80万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135602038","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135602038?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:33","pubTimestamp":1784108025,"startTime":"0","endTime":"0","summary":"歌禮製藥有限公司于2026年7月15日发布公告，披露当日在香港联交所场内回购普通股共200,000股，占已发行股本约0.0188%。本次回购每股价格介乎10.49港元至10.58港元，合计耗资约210.80万港元。公告显示，截至2026年7月14日，公司已发行股份为1,061,370,845股，库藏股份7,084,210股，合计1,068,455,055股。经本次回购后，因该批回购股份尚未注销，公司已发行股本仍维持上述规模。股东大会于2026年6月29日通过股份购回授权，授权公司可回购股份总数为106,137,084股。公告由公司秘书鍾明輝签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：7月15日回购20万股，耗资约210.80万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115242472","title":"歌礼制药-B：7月14日回购200,000股，耗资约209.00万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115242472","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115242472?lang=zh_cn&edition=full","pubTime":"2026-07-14 17:36","pubTimestamp":1784021764,"startTime":"0","endTime":"0","summary":"2026年7月14日，歌礼制药-B公告披露，当日于香港联交所回购200,000股普通股，约占公司已发行股本0.0188%。本次回购价格介乎每股10.19港元至11.31港元，总金额2,090,000港元。根据公告，截至2026年7月14日，歌礼制药-B已发行股本维持在1,061,370,845股，库存股份数为7,084,210股，合计已发行股本1,068,455,055股。购回授权于2026年6月29日获得通过，授权范围为可回购合计106,137,084股。公司确认本次回购严格遵守香港联合交易所有限公司证券上市规则及相关法律法规要求。公告由公司秘书钟明辉签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：7月14日回购200,000股，耗资约209.00万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651179148","title":"歌礼制药-B(01672)7月14日斥资209万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651179148","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651179148?lang=zh_cn&edition=full","pubTime":"2026-07-14 17:33","pubTimestamp":1784021634,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年7月14日，该公司斥资209万港元回购20万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","01672","BK1161","BK1191","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":0.0777},{"period":"1month","weight":-0.1078},{"period":"3month","weight":-0.529},{"period":"6month","weight":-0.3683},{"period":"1year","weight":-0.1859},{"period":"ytd","weight":-0.2081}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"歌礼制药有限公司是一家主要从事医药产品研发、生产和销售的投资控股公司。该公司专注于病毒性疾病、非酒精性脂肪性肝炎（NASH）或原发性胆汁性胆管炎（PBC）及肿瘤领域。该公司的产品管线包括用于慢性乙肝功能性治愈的ASC22、用于呼吸道合胞病毒（RSV）的ASC10、用于人类免疫缺陷病毒（HIV）功能性治愈的ASC22、用於新冠肺炎的ASC10及ASC11、用於NASH的ASC41、用於PBC的ASC42、用于实体瘤的ASC61、用于中、重度痤疮的ASC40等。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.146882},{"month":2,"riseRate":0.75,"avgChangeRate":0.100059},{"month":3,"riseRate":0.375,"avgChangeRate":-0.044472},{"month":4,"riseRate":0.375,"avgChangeRate":-0.053142},{"month":5,"riseRate":0.375,"avgChangeRate":-0.01034},{"month":6,"riseRate":0.375,"avgChangeRate":-0.053675},{"month":7,"riseRate":0.5,"avgChangeRate":0.009913},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.037953},{"month":9,"riseRate":0.125,"avgChangeRate":-0.072967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"歌礼制药-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}